

- Translation -

**Minutes of the 1/2025 Extraordinary General Meeting of Shareholders of  
Ramkhamhaeng Hospital Public Company Limited**

---

The meeting was held on Tuesday, June 10, 2025, at 10.00 A.M., at the meeting room on the 10th floor, Building 3, Ramkhamhaeng Hospital Public Company Limited, No. 436 Ramkhamhaeng Road, Hua Mak, Bangkok, Bangkok 10240.

The Company has set April 24, 2025, as the record date for determining the list of shareholders entitled to attend the 1/2025 Extraordinary General Meeting of Shareholders, there were 4,276 shareholders, representing a total of 1,200,000,000 shares.

**Meeting Quorum**

Miss Chanyawat Watthanaphongsaphat, the Company Secretary, informed the meeting that the 1/2025 Extraordinary General Meeting of Shareholders of Ramkhamhaeng Hospital Public Company Limited (“**the Company**” or “**RAM**”) was attended by 20 shareholders in person, representing 111,457,811 shares, and by 59 proxies, representing 874,727,955 shares. In total, there were 79 shareholders attending the meeting, representing 986,185,766 shares, which constitutes 82.1821 percent of the total issued shares of the Company, thus constituting a quorum in accordance with the Company’s Articles of Association.

The Company Secretary then introduced the directors, executives, financial advisors, and legal advisors present at the meeting as follows:

**Directors attending the Meeting in person**

1. Dr. Pitchaya Somburanasin, M.D. Chairman of the Board of Directors, Chairman of Group Executive Committee and Member of the Risk Management and Investment Committee
2. Dr. Rukkagee Kanjanapitak (PH.D.) Director, Member of Group Executive Committee, Member of the Risk Management and Investment Committee, Member of the Nomination and Remuneration Committee and Group Chief Executive Officer

3. Dr. Suthee Leelasetakul, M.D. Director, Member of Group Executive Committee and Chief Executive Officer of Ramkhamhaeng Hospital
4. Dr. Jernpol Bhumitrakul, DDS. Director, Member of Group Executive Committee, Group Chief Operating Officer and Chief Affiliate Hospital Group 1
5. Dr. Siripong Luengvarinkul, M.D. Director, Member of Group Executive Committee and Chief Affiliate Hospital Group 2
6. Mr. Talit Chuen-Im Director, Member of Group Executive Committee, Member of the Risk Management and Investment Committee and Executive Vice President, Northeastern Hospital Group
7. Miss Tassawan Sirivongs Director
8. Mr. Benny Lim Director, Member of the Risk Management and Investment Committee and Member of the Nomination and Remuneration Committee
9. Mr. Pramol Apirat Independent Director and Chariman of Audit Committee
10. Miss Kittiyarat Jirojdamrongchai Independent Director and Member of Audit Committee
11. Mr. Kajit Habanananda Independent Director, Member of Audit Committee and Member of the Nomination and Remuneration Committee
12. Dr. Somsri Pausawasdi (M.D.) Independent Director and Member of the Nomination and Remuneration Committee

**Directors attending the Meeting via electronic media**

1. Dr. Pinit Hirunyachote, M.D. Independent Director and Member of the Nomination and Remuneration Committee
2. Miss Cheryl Ang Yan Qi Director

A total of 14 directors of the Company attended the meeting out of all 15 directors, representing 93.33 percent of the total number of directors.

**Executive attending the Meeting in person**

1. Dr. Pramuk Unachak (M.D.)                      Member of Group Executive Committee and Executive Vice President, Northern Hospital Group
2. Mr. Surabot Visutimatakul                      Chief Financial Officer

**Financial Advisor attending the Meeting in person**

1. Mr. Disapong Jaipakdeemun                      D Capital Advisory Co., Ltd.
2. Miss Kanyarat Kanaprach                      D Capital Advisory Co., Ltd.

**Legal Advisor attending the Meeting in person**

1. Miss Pornpan Chayasuntorn                      Linklaters (Thailand) Ltd.
2. Mr. Paveen Khiewwichit                      Linklaters (Thailand) Ltd.

The Company invited legal advisors from Linklaters (Thailand) Limited to act as witnesses for the vote counting process at this meeting.

OJ International Co., Ltd. was an inspection for the registration and voting system for this meeting.

**Preliminary Proceeding before the Meeting**

Before proceeding with the agenda items, the Company Secretary informed the meeting that the Company would collect, use, and disclose the personal data of all attendees by recording photographs and video for the purposes of recording and preparing the minutes of the meeting, as well as for managing the meeting. The Company Secretary then explained the procedures and guidelines for the meeting as follows:

1. The meeting will consider matters in accordance with the agendas in the invitation letter. Information will be presented for each agenda, and shareholders will be given the opportunity to ask questions before voting. The voting results will be announced to the meeting once the vote counting for each agenda has been completed.
2. Voting Procedure

- 2.1 In casting votes, one (1) share shall have one (1) vote. Therefore, each shareholder shall have votes equal to the number of shares he/she hold or have been granted proxy authority for.
  - 2.2 For this meeting, there are a total of 2 agenda proposed for the shareholders' consideration. Agenda 1 require the majority vote of shareholders attending the meeting and casting their votes. Agenda 2 requires approval by not less than three-fourths (3/4) of the total votes of the shareholders who attend the meeting and are entitled to vote. Agenda 3 is for other matters; the Company will allow shareholders to ask questions or express opinions as appropriate.
  - 2.3 In casting votes, the Company will collect ballot cards only from shareholders who vote "disapprove" or "abstain." For each agenda, the meeting will be asked whether there are any votes of disapproval or abstention. If there are, shareholders or proxy holders are requested to submit their completed and signed ballot cards to the Company's staff.
  - 2.4 In vote-counting, the Company will deduct the number of votes marked as "disapprove" and "abstain" from the total number of votes of shareholders present or casting votes. The remaining votes will be considered as votes "Approve"
3. Questioning and Commenting Procedure
    - 3.1 Before voting on each agenda, shareholders will be given the opportunity to ask questions or express opinions related to that agenda, as appropriate. The Company will provide responses to relevant questions during the discussion of the corresponding agenda. However, in the event of a large number of questions, the Company reserves the right to select questions as deemed appropriate. Some questions may be addressed at the end of the meeting or published on the Company's website.
    - 3.2 For shareholders who granted proxies to others to attend the meeting and selected the proxy form specifying their voting, the Company has already recorded their votes—whether in approve, disapprove, or abstained—according to their instructions in the registration system for use in the resolution of each agenda.
    - 3.3 Once the voting is closed, the Company will process the results and announce the vote result to the meeting for each agenda.

4. The Company will publish the meeting minutes in both Thai and English on the Company's website, and will notify the publication of the meeting minutes through the Information Disclosure System of the Stock Exchange of Thailand within 14 days from the date of the meeting.

**Commencement of the Meeting**

Dr. Pitchaya Somburanasin, Chairman of the Board of Directors, served as the Chairman of the Meeting ("**the Chairman**"). He welcomed the shareholders and appointed Miss Chanyawat Watthanaphongsaphat, the Company Secretary, to serve as the Secretary of the Meeting ("**the Secretary**"). The Chairman then proposed that the meeting consider the matters in accordance with the agendas in the invitation to the shareholder meeting, as follows:"

**Agenda 1 To consider and certify the minutes of meeting of the Annual General Meeting of Shareholders for the year 2025 on April 30, 2025**

The Chairman assigned the Secretary to propose that the meeting certify the minute of meeting of the Annual General Meeting of Shareholders for the year 2025 on April 30, 2025 as follows:

the Company held the Annual General Meeting of Shareholders for the year 2025 on April 30, 2025, with the minutes of the meeting appearing in Enclosure 1 , in which the Company has published a copy of the said minutes of the meeting on the Company's website (<http://www.ram-hosp.co.th>) for shareholders to acknowledge and verify the correctness. The meeting minutes were sent to the Stock Exchange of Thailand and the Ministry of Commerce within the time frame specified by law.

The Board of Directors has considered that the minutes of the meeting have been recorded accurately and completely. Therefore, it is deemed appropriate to propose to the 1/2025 Extraordinary General Meeting of Shareholders to consider and certify the minutes of the meeting.

The Secretary gave shareholders the opportunity to ask questions regarding the minutes of meeting of Annual General Meeting of Shareholders for the year 2025 on April 30, 2025. There are no questions were raised.

The Secretary proposed that the meeting consider and certify the minute of meeting of the Annual General Meeting of Shareholders for the year 2025 on April 30, 2025. This agenda requires the majority vote of shareholders attending the meeting and casting their votes.

**Resolution:** The meeting resolved to certify the minute of meeting of the Annual General Meeting of Shareholders for the year 2025 on April 30, 2025, with the following votes:

<b>Shareholders entitled to vote</b>	<b>Number of votes (shares)</b>	<b>Percentage</b>
Approved	986,487,866	100.0000
Disapproved	0	0.0000
Abstained	0	0.0000
Voided Ballot	0	0.0000
	<b>986,487,866</b>	<b>100.0000</b>

**Agenda 2 To consider and approve additional investment in Thonburi Healthcare Group Public Company Limited’s ordinary shares which may be deemed as an acquisition of the business of another company as the Company’s own**

The Chairman assigned Mr. Disapong Jaipakdeemun (Financial advisor) to propose the shareholders to consider and approve the additional investment in Thonburi Healthcare Group Public Company Limited’s ordinary shares which may be deemed as an acquisition of the business of another company as the Company’s own as follows:

In additional investment in Thonburi Healthcare Group Public Company Limited’s ordinary shares is in-line with the Company’s strategic growth plan, to become one of Thailand’s leading private hospital groups, through strengthening treatment capabilities, expanding the patient base, and generating long-term sustainable revenue and profits for the Company’s shareholders. This includes investing in hospital groups with high potential, advanced medical capabilities, and a strong nationwide network. The hospital locations of the Company and Thonburi Healthcare Group Public Company Limited (“THG”) do not overlap and there is no direct competition in terms of geographical medical service coverage, while the patient base have a broad range including self-pay patients, patients under the Social Security scheme, patients under the National Health Security Office and international patients (medical tourism).

The Company will acquire the newly issued ordinary shares of THG offered exclusively to the Company through a private placement, totaling 430,500,000 shares, with a par value of THB 1.00 per share, at an offering price of THB 8.65 per share, amounting to a total value of THB 3,723,825,000 (the “Acquisition of THG’s PP Shares”). Currently, the Company holds 208,378,474 shares in THG, representing 24.59% of THG’s total issued and paid-up shares. After the completion of the Acquisition of THG’s PP Shares, the Company will hold 638,878,474 shares in THG, representing 49.99% of THG’s total issued and paid-up shares (after the registration of the capital increase for the newly issued ordinary shares offered through the private placement).

Following the completion of the Acquisition of THG’s PP Shares, the Company’s shareholding in THG will increase from 24.59% to 49.99% of THG’s total issued and paid-up shares (after the registration of the paid-up capital increase for the newly issued ordinary shares of THG offered through the private placement). As a result, the Company will acquire additional ordinary shares in THG, crossing the 25.00% threshold of the total voting rights of THG, which triggers an obligation to make a mandatory tender offer for all securities of THG pursuant to the Notification of the Capital Market Supervisory Board No. TorChor. 12/2554 Re: Rules, Conditions and Procedures for the Acquisition of Securities for Business Takeovers, dated 13 May 2011 (as amended) (“Notification TorChor. 12/2554”).

However, the Company intends to apply for a waiver of such mandatory tender offer obligation resulting from the Acquisition of THG’s PP Shares by virtue of a resolution of the shareholders’ meeting of the business (Whitewash) from the Office of the Securities and Exchange Commission (“SEC”) in accordance with the Notification of the Office of the Securities and Exchange Commission No. SorKor. 29/2561 Re: Rules for Requesting a Waiver from the Requirement to Make a Tender Offer for All Securities of the Business by Virtue of a Resolution of the Shareholders’ Meeting of the Business, dated 30 May 2018 (as amended) (“Notification SorKor. 29/2561”) (the “Whitewash Waiver”).

Following the Company’s receipt of the Whitewash Waiver from the SEC and the completion of the Acquisition of THG’s PP Shares, resulting in the Company holding 49.99% of THG’s total issued and paid-up shares (after the registration of the capital increase for the newly issued ordinary shares offered through the private placement), THG will proceed with offering newly issued ordinary shares to its existing shareholders in proportion to their respective shareholdings (Rights Offering), totaling 511,186,960 shares, with a par value of

THB 1.00 per share. The allocation ratio will be 5 existing ordinary shares to 2 newly issued ordinary shares (calculated based on the total number of shares after the registration of the capital increase for the newly issued shares offered through the private placement), at an offering price of THB 5.00 per share. The Company will exercise its rights to subscribe for the newly issued ordinary shares in proportion to its shareholding in THG to maintain its ownership percentage, and the Company will not exercise the right to oversubscribe for the newly issued ordinary shares (“Subscription of THG’s RO Shares”).

If other shareholders of THG fully exercise their rights to subscribe for the newly issued ordinary shares offered to existing shareholders in proportion to their respective shareholdings (Rights Offering), the Company’s shareholding in THG will remain at 49.99% of the total voting rights of THG after the registration of the paid-up capital increase for the newly issued ordinary shares offered through the Rights Offering. Conversely, if no other shareholders of THG exercise their rights to subscribe for the newly issued ordinary shares offered through the Rights Offering, the Company’s shareholding in THG may increase to a maximum of 58.33% of the total voting rights of THG after the registration of the capital increase for such shares. In such a case, the Company will not be obligated to make a mandatory tender offer for all securities of THG, as the transaction qualifies for an exemption under the rules prescribed in Notification TorChor. 12/2554. Furthermore, at present, the Company has no intention of acquiring any additional shares in THG following the subscription of the newly issued ordinary shares under the Rights Offering that would result in the Company being required to make a mandatory tender offer for all securities of THG under the criteria set forth in Notification TorChor. 12/2554.

The Company intends to finance the Acquisition of THG’s PP Shares and the Subscription of THG’s RO Shares entirely through borrowings from local financial institutions and has a plan for the loan repayment. However, the borrowings for this additional investment in THG may potentially, at certain points in time, cause the Company to be temporarily non-compliant with some financial covenants under existing loan agreements with other financial institutions. To prevent any potential breach of such financial covenants in the future, the Company has proactively submitted waiver requests for such financial covenant requirements to the relevant financial institutions and expects to obtain the necessary waivers prior to entering into the transaction.

Regardless of whether the Company holds 49.99% (in the event that all other THG shareholders fully subscribe to the Rights Offering) or 58.33% (in the event that no other THG shareholders subscribe to the Rights Offering) of the total voting rights in THG after the registration of the paid-up capital increase for the newly issued ordinary shares offered through the Rights Offering, THG will be considered a subsidiary of the Company. Accordingly, the Company will be required to prepare consolidated financial statements in accordance with the relevant accounting standards, starting from the date THG becomes a subsidiary of the Company, which will be after the completion of the capital increase. THG will use the proceeds from the capital increase for loan repayments and as working capital as specified, which will enhance THG's financial position, reduce its interest expense, lower its debt-to-equity ratio, and ultimately result in improving consolidated financial performance for the Company.

To ensure flexibility and efficiency in carrying out the necessary actions relating to the Additional Investment in the newly issued ordinary shares of THG as proposed above, it is proposed that the shareholders' meeting consider and approve the authorization of the Company's Board of Directors, or any person authorized by the Board of Directors, to be empowered to take all actions relating to the Acquisition of THG's PP Shares, the Whitewash Waiver application, and the Subscription of THG's RO Shares. Such authority should include, but not be limited to, the following:

(a) To negotiate, agree, amend, modify, finalize, and complete the terms and conditions as well as any other details relating to the Acquisition of THG's PP Shares, the Whitewash Waiver application, and the Subscription of THG's RO Shares, including any related transactions (such as financing arrangements and/or borrowing or providing guarantees);

(b) To negotiate, agree, amend, modify, execute, certify, finalize, and deliver contracts, notices, consents, waivers, or any other documents related to the Acquisition of THG's PP Shares, the Whitewash Waiver application, and the Subscription of THG's RO Shares, including any related transactions (such as documents concerning financing arrangements and/or borrowing or providing guarantees); and/or

(c) To perform any acts and execute any documents as necessary or deemed appropriate to ensure the completion of the Acquisition of THG's PP Shares, the Whitewash

Waiver application, and the Subscription of THG's RO Shares, including any other related transactions.

**The Board of Directors' Opinion:**

With respect to the acquisition of THG's newly issued ordinary shares offered through a private placement, the Board of Directors has considered and deemed that the price, value, and terms and conditions under the share subscription agreement between the Company and THG are appropriate. Following the receipt of the Whitewash Waiver from the SEC and the completion of the acquisition of THG's PP Shares, the Company will hold 49.99% of THG's total issued and paid-up shares. The use of proceeds from the capital increase has been specified for the repayment of existing loan obligations of THG and/or its subsidiaries, which will result in an improved financial position for THG. Such an improvement is expected to benefit the Company, as a shareholder of THG, through an appropriate return on investment in the form of dividends.

With respect to the subscription of newly issued ordinary shares of THG offered to existing shareholders in proportion to their shareholding (Rights Offering), the Board of Directors of the Company considers the subscription price and value of the RO Shares to be fair and equitable to all shareholders of THG. THG may receive capital increase proceeds from other shareholders, which would provide sufficient funds for loan repayments and working capital to THG. This will help further strengthen THG's financial position, which will ultimately benefit the Company as a shareholder of THG in the long term.

Regarding the corporate governance of THG, which will become a subsidiary of the Company following the completion of the Additional Investment Transactions in THG, the Company currently has no plan to nominate any additional directors to THG's board of directors within the next 12 months, despite the fact that the number of THG directors nominated by the Company (3 out of a total of 18 directors) does not correspond to the Company's shareholding proportion in THG. The Company considers that the current board of directors of THG comprises individuals with the necessary qualifications, expertise, and experience appropriate for the management and operation of THG's business. In addition, the Company plans to propose that THG's Board of Directors consider establishing a Business Unit Executive Committee for each hospital within the THG group. This initiative aims to enhance operational efficiency, promote transparency, and support THG's board in overseeing, reviewing, and screening the performance and operations of each hospital in

accordance with good corporate governance principles. The Company's board of directors believes that this approach is consistent with the Company's corporate governance policy for its subsidiaries and will yield long-term benefits to the Company as a shareholder of THG.

As for the source of funds used for the Additional Investment Transactions in THG, which are entirely financed through borrowings from local financial institutions and for which the Company has already executed loan agreement, the Board of Directors of the Company has considered and views that the terms and conditions of such loan agreements are appropriate, and that the Company has the financial capability to comply with the loan covenants and to repay such borrowings accordingly.

Therefore, the Board of Directors has resolved to propose that the 1/2025 Extraordinary General Meeting of Shareholders consider and approve Additional Investment Transactions in THG, together with the relevant authorizations as described above.

The Secretary gave shareholders the opportunity to ask questions regarding additional investment in Thonburi Healthcare Group Public Company Limited's ordinary shares which may be deemed as an acquisition of the business of another company as the Company's own. There are additional comments or inquiries, which can be summarized as follows:

**1. Mr. Wichian Panametha (Shareholder)**

■ **Expansion through Brownfield investments**

Dr. Rukkagee Kanjanapitak explained that Brownfield investment refers to investing in existing hospital businesses that are already in operation, allowing the Company to recognize revenue and profit immediately. This differs from Greenfield investment, which involves constructing a new hospital from the ground up and requires time after opening to build a patient base and generate operating profit—for example, Ramkhamhaeng Hospital 2 or other Ramkhamhaeng affiliated hospitals in upcountry areas.

■ **Criteria for a Waiver from Mandatory Tender Offer (Whitewash)**

Mr. Disapong Jaipakdeemun explained that investing in a public company listed on the Stock Exchange of Thailand, if the acquisition of shares reaches a point that triggers a mandatory tender offer—specifically at 25%, 50%, or 75% (Trigger Points)—the Company is obligated to make a tender offer for all securities of that company. However, the Company may apply for a waiver

from the mandatory tender offer with the Securities and Exchange Commission (SEC) by obtaining a resolution from the shareholders' meeting of the target company (a "Whitewash") in accordance with Form 247-7. This requires the approval of not less than three-fourths (3/4) of the total votes of shareholders who attend the meeting and are entitled to vote, excluding the votes of the party requesting the waiver (RAM).

On June 9, 2025, the shareholders' meeting of Thonburi Healthcare Group Public Company Limited resolved to approve the waiver.

■ **Difference between Investment Proportions of 49.99% and 50.00%**

Mr. Disapong Jaipakdeemun explained that if the Company were to acquire more than 50.00% of the newly issued ordinary shares under a Private Placement (PP) of THG, the rules and conditions for a Whitewash waiver would become significantly more complicated. Therefore, the Company does not intend to proceed with an investment at such a level.

2. **Mrs. Kasina Srisa-an (Proxy from the Thai Investors Association)**

- **How will borrowing from financial institutions for this investment affect the Company's financial position? It is noted that this could result in a significantly higher debt-to-equity (D/E) ratio in the Company's financial statements.**

Dr. Rukkagee Kanjanapitak explained that the impact from borrowing 5,000 million baht for this investment may result in a significant increase in certain financial ratios. However, the Company has already negotiated and obtained waivers from the financial institutions regarding these matters.

■ **Loan repayment plan**

Dr. Rukkagee Kanjanapitak explained that the Company's Board of Directors has considered selling non-core assets as a source of funds for loan repayment. These may include the sale of listed securities to enhance the Company's liquidity (Available for Sale), a golf course, or certain hospital businesses. The Company believes it has the capability to comply with the loan agreement conditions and to repay both the principal and interest of the loan.

3. Miss Bussakorn Ngampasuthadon (Shareholder)

- **What is the significance and necessity of the additional investment in the ordinary shares of Thonburi Healthcare Group Public Company Limited (“THG”)?**

Dr. Rukkagee Kanjanapitak explained that long-term business growth cannot be assessed based solely on the past three years, as that period coincided with the COVID-19 pandemic, during which hospital businesses experienced unusually high performance.

Currently, the Company is the major shareholder of THG, holding 24.59% of its shares. The Company sees strong growth potential in THG’s business. However, the operating challenges faced by THG in 2024 did not stem from its hospital operations but from other factors, such as substantial investments in certain loss-making assets and the detection of suspicious transactions, which THG has already disclosed. Therefore, if the Company does not to proceed with further investment in THG, it could lead to liquidity problems for THG and, in turn, negatively affect the Company as its major shareholder.

Moreover, passing up this investment opportunity would mean missing the chance to invest in a business with solid potential. Thonburi Hospital 1, THG’s flagship hospital, has long been recognized for its reputable and quality healthcare services.

- **Will this investment result in the loss of opportunities to invest in other projects that may yield better returns?**

Dr. Rukkagee Kanjanapitak explained that over the past two years, the Company has been planning to make additional investments in hospital businesses both domestically and internationally. When comparing Greenfield investments (new construction projects) with Brownfield investments (acquiring existing hospitals that can generate immediate profits), the investment in THG is considered a Brownfield investment that can deliver immediate returns.

Moreover, this investment will strengthen the Company’s overall business, enhance its bargaining power in the procurement of medical equipment and supplies, and allow for greater influence in setting strategic business

directions. All of this is aimed at maximizing long-term returns for the Company's shareholders.

There were no further questions and comments from shareholders on this agenda. The Secretary proposed that the meeting consider and approve additional investment in Thonburi Healthcare Group Public Company Limited's ordinary shares which may be deemed as an acquisition of the business of another company as the Company's own. This agenda requires approval by not less than three-fourths (3/4) of the total votes of the shareholders who attend the meeting and are entitled to vote.

**Resolution:** The meeting resolved to approve additional investment in Thonburi Healthcare Group Public Company Limited's ordinary shares which may be deemed as an acquisition of the business of another company as the Company's own, with the following votes:

<b>Shareholders entitled to vote</b>	<b>Number of votes (shares)</b>	<b>Percentage</b>
Approved	986,513,586	100.0000
Disapproved	0	0.0000
Abstained	0	0.0000
Voided Ballot	0	0.0000
	<b>986,513,586</b>	<b>100.0000</b>

**Agenda 3 Other Matters (if any)**

There are no shareholders proposed any additional agenda, the Secretary gave shareholders the opportunity to ask further questions. There are additional comments or inquiries, which can be summarized as follows:

- 1. Anonymous shareholder**
  - **Will the ongoing construction at the front of Ramkhamhaeng Hospital 2 (RAM 2) affect the operating results of RAM 2?**

Dr. Siripong Luengvarinkul explained that the construction is for the electric train, which may require RAM 2 to renovate the front construction area

accordingly. RAM 2 plans to enhance the frontage to make it more attractive and replace the hospital signage to improve visibility.

For RAM 2's operating performance, it has grown faster than expected. RAM 2 will officially open the 4-dimensional radiation therapy center, with the opening ceremony held on Friday, June 27, 2025.

**2. Mr. Wichian Panametha (Shareholder)**

■ **The parking design of RAM 1 and RAM 2**

Dr. Siripong Luengvarinkul explained that previous directors compared between constructing a parking building and purchasing land to build a parking lot. They concluded that investing in purchasing land to build a parking lot has a lower cost per parking space than constructing a parking building. Additionally, this increases the land's value for the future and provides opportunities for business expansion using the land held.

For RAM 1, the company is currently considering the construction a parking building and expanding service areas using the existing parking lot land.

No other matters were proposed for consideration. The Chairman then thanked the shareholders for attending the meeting and adjourned the meeting.

**The meeting was adjourned at 11.30 A.M.**

\_\_\_\_\_ - Signature - \_\_\_\_\_ Chairman of the meeting  
(Dr. Pitchaya Somburanasin, M.D.)

\_\_\_\_\_ - Signature - \_\_\_\_\_ Company Secretary  
(Miss Chanyawat Watthanaphongsaphat)